Key clinical point: Obinutuzumab and ibrutinib induction followed by a minimal residual disease–driven strategy in patients with chronic lymphocytic leukemia (CLL) resulted in a high long-term complete response rate and prolonged survival.
Major finding: The intention-to-treat complete response rate at 16 months was 62%.
Study details: A phase 2 study of 135 patients with CLL.
Disclosures: ICLL-07 FILO was funded by Roche and Janssen. Dr. Michallet reported having no disclosures.
Michellat A-S et al. iwCLL 2019, Abstract 1962.